In its recently completed Phase 2 trial in participants with moderate to severe major depressive disorder, Cybin reported that at four months after dosing, 75% of patients receiving two 16mg doses of CYB003 achieved remission from depression symptoms. With the Phase 2 trial data, the
The Phase 3 trial for CYB003 is planned to commence enrollment mid-2024 and focus on its safety and efficacy. CCR's
"The Phase 2 results from the CYB003 trials were impressive and demonstrated the potential for treating a serious condition that affects over 20 million Americans," said
"With many drug candidates advancing to later stages of clinical trials, 2024 is turning out to be a critical year for psychedelic-assisted therapy," added
To learn more about enrolling in the CYB003 Phase 3 Trial, please visit this link.
Learn more at www.numinus.com and follow us on LinkedIn, Facebook, and Instagram.
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements, including challenges and uncertainties inherent in product and/or treatment development and in the psychedelics industry generally, availably of suitable subjects, the uncertainties of clinical success, the possibility of adverse events, and the timeline for the availability of the treatment under investigation; the laws, challenges and risks involved in the production of a psychedelics drug; and the uncertainty of the level of demand, uptake and/or insurance coverage for treatment other risks that are set forth in and other risks that are set forth in our annual information form dated
View original content to download multimedia:https://www.prnewswire.com/news-releases/cedar-clinical-research-selected-as-clinical-research-site-for-cybins-phase-3-study-of-cyb003-302119083.html
SOURCE
© Canada Newswire, source